The first event is the Drug Delivery & Formulation (DDF) Summit, Berlin, Germany where Joel Hellrup today, June 3, presents: “PharmaShell® – The high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision.”

Nanexa will then continue its international presence at the following events:

• BIO International Convention in Boston, USA – a forum for creating strategic partnerships and licensing opportunities (June)
• American Diabetes Association (ADA) Scientific Sessions in Chicago, USA – where the company’s Phase I data for NEX-22 has been accepted as a Late Breaking Abstract and will be presented as a poster (June)
• Controlled Release Society (CRS) Annual Meeting in Philadelphia, USA – where Nanexa will have a one-hour oral presentation on PharmaShell® (July)

NEX-22 is a once-monthly depot of the GLP-1 analogue liraglutide, developed using the PharmaShell® technology. In the recently completed Phase I study, NEX-22 demonstrated a dose-proportional increase in exposure and a controlled release of the drug over one month following a single subcutaneous injection. The results strengthen the potential for once-monthly treatment of type 2 diabetes and have generated significant interest from potential partners.

“That our abstract on NEX-22 is being presented at ADA is an important recognition of our data,” said David Westberg, CEO of Nanexa. “We also look forward to presenting our progress at both BIO and CRS, including one-on-one meetings with several interesting companies to discuss potential collaborations. This exposure period is an important step in our business development and strengthens our position in the diabetes and obesity area, while enabling PharmaShell® as a drug delivery platform for both well known and novel pharmaceutical compounds.”